Evusheld monoclonal antibody treatment now available at Synergy Wellness to prevent COVID-19
Synergy Wellness now offers Evusheld for those at high risk for contracting and succumbing to COVID-19. Evusheld has been shown to decrease the rate of COVID-19 infections by 83% over 6 months. But due to limited quantities at this time, those at the highest risk will be prioritized per FDA guidelines. These include individuals with immunocompromising conditions such as organ transplant recipients and cancer patients undergoing active chemotherapy, or any patient taking high dose immunosuppressants. Here’s the EUA for Evusheld:
The U.S. Food and Drug Administration has issued an EUA for the emergency use of the unapproved product EVUSHELD (tixagevimab co-packaged with cilgavimab), SARS-CoV-2 spike protein-directed attachment inhibitor, for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):
- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2 and
- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID19 vaccine component(s).
Synergy Wellness will administer Evusheld in clean procedure rooms with utmost attention to infection control. There will be NO testing or sick patients in close proximity, with all staff and patients in masks and gloves.